NCT05886478View on ClinicalTrials.gov

A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin

CompletedOBSERVATIONAL
Enrollment

26

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
T-Cell Lymphoma
Interventions
DRUG

No intervention

As this is an observational study, no intervention will be administered.

Trial Locations (11)

10126

AZ OSP Citta' Della Salute (Torino), Torino

20122

Ospedale Maggiore Policlinico, Milan

33075

Hopital Saint Andre, Bordeaux

37075

Universitätsmedizin Göttingen, Göttingen

67063

Klinikum Ludwigshafen, Hautklinik, Ludwigshafen

75010

Hopital Saint Louis, Paris

76031

CHU Roeun, Rouen

97080

Universitätsklinikum Würzburg, Würzburg

08036

Hospital Clinic, Barcelona, Barcelona

08908

ICO Hospitalet, Barcelona, Barcelona

07120

Hospital Son Espases, Palma

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05886478 - A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin | Biotech Hunter | Biotech Hunter